论文部分内容阅读
目的:评价哌拉西林/他唑巴坦治疗小儿先天性巨结肠肠炎的疗效和安全性。方法:先天性巨结肠肠炎住院患儿122例随机分为两组。观察组72例应用哌拉西林/他唑巴坦钠治疗;对照组50例应用头孢哌酮/舒巴坦钠治疗。两组疗程均为7~14 d。比较两组患儿治疗前后C反应蛋白差值、白细胞计数差值和中性粒细胞百分比差值,以及两组平均治疗时间,评价两组临床疗效、细菌清除率和安全性。结果:两组治疗前后C蛋白差值、白细胞计数差值、中性粒细胞百分比差值等比较,差异无统计学意义(P>0.05)。观察组与对照组有效率分别为86.11%和88.00%(P>0.05)。全部患儿致病菌阳性率为75.41%,以大肠埃希菌为首位致病菌。观察组细菌清除率为85.96%,高于对照组的80.00%(P<0.05)。两组患儿均未发生药品不良反应。结论:哌拉西林/他唑巴坦治疗小儿先天性巨结肠肠炎疗效更显,而且未见不良反应。
Objective: To evaluate the efficacy and safety of piperacillin / tazobactam in the treatment of children with Hirschsprung’s disease. Methods: 122 hospitalized children with Hirschsprung’s disease were randomly divided into two groups. 72 cases in the observation group were treated with piperacillin / tazobactam sodium and 50 cases in the control group were treated with cefoperazone / sulbactam sodium. The two courses of treatment were 7 to 14 days. The differences of C-reactive protein, white blood cell count and neutrophil percentage before and after treatment were compared between the two groups. The average treatment time was compared between two groups to evaluate the clinical efficacy, bacterial clearance rate and safety. Results: There was no significant difference in protein differential, leukocyte count, neutrophil percentage difference between the two groups before and after treatment (P> 0.05). The effective rate of observation group and control group were 86.11% and 88.00% (P> 0.05). The positive rate of all children with pathogenic bacteria was 75.41%, with Escherichia coli as the first pathogen. The bacterial clearance in the observation group was 85.96%, which was higher than 80.00% in the control group (P <0.05). Two groups of children did not occur adverse drug reactions. CONCLUSION: Piperacillin / tazobactam is more effective in treating Hirschsprung’s disease in children and has no adverse reactions.